Zoonoses

Study Shows Masks Reduce Spread Of Virus In Classrooms

Retrieved on: 
Saturday, September 4, 2021
Occupational safety and health, Health, Hygiene, Ultraviolet radiation, Electromagnetic radiation, Articles, Public health, COVID-19, Zoonoses, Ultraviolet germicidal irradiation, Disinfectant, Ultraviolet

Now, with the new school year upon us, the CDC has provided guidelines including mask-wearing inside at school.

Key Points: 
  • Now, with the new school year upon us, the CDC has provided guidelines including mask-wearing inside at school.
  • Dr. Arthur Kreitenberg, Chief Innovation & Technology Officer and Co-Founder of Dimer said: "We advocate for objective and informed decision making and this demonstrative study affirms that mask-wearing reduces the spread of infectious germs like COVID-19.
  • We hope that schools and parents will take a look at the demonstration we conducted and be more informed."
  • The particles in thesimulation are 10x larger than a virus.

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

Retrieved on: 
Wednesday, August 4, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, Variants of SARS-CoV-2

Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.

Key Points: 
  • Based on this screening effort, the most efficacious derivative (Salicyn-30) was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection.
  • This analysis demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in COVID-19 infections.
  • Moreover, based on their mechanism of action, Salicyn-30 and other lead compounds may be equally effective against recent emerging SARS-CoV-2 variants.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Radiology, Stem cells, Medical Supplies, COVID-19, Occupational safety and health, Public health, Zoonoses, Health, Medical specialties

The "Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global live cell imaging market.
  • The global live cell imaging market is expected to grow from $3.61 billion in 2020 to $3.98 billion in 2021 at a compound annual growth rate (CAGR) of 10.3%.
  • The live cell imaging market consists of sales of live cell imaging by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing and selling live cell imaging equipment and consumables.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology

Retrieved on: 
Tuesday, August 3, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Ondine

Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.

Key Points: 
  • Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many pathogens including MRSA, Candida auris and SARS-Cov-2.
  • Dr. Nicolas Loebel, Ondine Biomedicals President and Chief Technology Officer, will present the results in the Photomedicine and SARS-CoV-2/ASP-ESP Symposium.
  • Ondine Biomedical Inc. is a Canadian headquartered, medical device company led by Founder and CEO, Carolyn Cross.

DGAP-News: Biotest AG: Biotest proves the mode of action of trimodulin for the treatment of COVID-19

Retrieved on: 
Tuesday, August 3, 2021
Occupational safety and health, COVID-19, Public health, Zoonoses, Health, Medical specialties

First impressive preclinical data on the mode of action of trimodulin in COVID-19 have been published by Biotest in renowned international scientific journals "Frontiers in Immunology" and "Biomedicines".

Key Points: 
  • First impressive preclinical data on the mode of action of trimodulin in COVID-19 have been published by Biotest in renowned international scientific journals "Frontiers in Immunology" and "Biomedicines".
  • [2]
    The two papers provide the basis for the mechanism of action of trimodulin in COVID-19.
  • Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with severe COVID-19.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research

Retrieved on: 
Monday, August 2, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Brilacidin, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus, COVID-19, Antiviral drug, Severe acute respiratory syndrome

WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.

Key Points: 
  • WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.
  • Brilacidin SARS-CoV-2 Manuscript: Scientists conducting laboratory testing of Brilacidin, in particular its ability to block entry of SARS-CoV-2 into human cells, have submitted their research findings for peer-review publication.
  • These data include insights into Brilacidins antiviral mechanisms of action and Brilacidin activity against the Alpha (B.1.1.7) and Gamma (P.1) SARS-CoV-2 variants.
  • Taken together, the results from ongoing lab research into Brilacidins antiviral properties by different groups of scientists only strengthens our belief in Brilacidin, said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

SaNOtize inks agreement with Indian biotech Glenmark to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Retrieved on: 
Monday, August 2, 2021
Other Manufacturing, Research, Clinical trials, Public policy, Government, Healthcare reform, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Epidemiology, Health sciences, Health, Articles, Infectious diseases, Global health, Pandemics, Virus, Zoonoses, Nitric oxide, Infection, Antimicrobial, SaNOtize, Glenmark Pharmaceuticals Ltd, SANOTIZE, GLENMARK PHARMACEUTICALS LTD

Available as a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.

Key Points: 
  • Available as a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
  • The committee has recommended a Phase III clinical trial to be conducted in Indian patients in the weeks to follow.
  • SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent microbial infections in 2017.
  • SaNOtize Research & Development Corp. is a biotech company based in Vancouver, BC working to commercialize the multi-faceted antimicrobial properties of a liquid that produces nitric oxide.